The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Evening Standard
6 hours ago
- Evening Standard
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers.
Reuters
7 hours ago
- Reuters
Lilly expects orforglipron obesity results in third quarter
June 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes. Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company. The U.S. Food and Drug Administration typically makes new drug approval decisions 10 months after a manufacturer's submission. Lilly said it plans to file for regulatory approvals for orforglipron as a diabetes treatment in 2026. Full results of the diabetes trial were presented at the annual meeting of the American Diabetes Association in Chicago. The Phase 3 study showed that type 2 diabetes patients taking the highest dose of daily orforglipron lost nearly 8% of their body weight over 40 weeks. That compares favorably with Novo Nordisk's ( opens new tab injected drug Ozempic, for which trials showed that diabetic patients on the highest dose lost roughly 6% of their body weight. Lilly's pill, which can be taken without food or water, lowered blood sugar levels by an average of 1.3% to 1.6% across doses. The company said the most frequently reported side effects were gastrointestinal and similar to other GLP-1 drugs, including diarrhea and vomiting. Custer said Lilly's goal in its non-diabetes trials is to achieve weight loss consistent with GLP-1 drugs that are currently available. Ozempic was shown in trials to lead to weight loss of 15% for people without diabetes over 68 weeks. He said orforglipron, which has a simpler production process than injected GLP-1 drugs such as Ozempic or Lilly's Zepbound and does not require cold storage, could mean wider global access to weight-loss drugs. "This is the type of molecule that is going to allow us to reach the broader globe," Custer said. The executive declined to comment on pricing plans for orforglipron.
Scottish Sun
7 hours ago
- Scottish Sun
New ‘Ozempic pill' is better than ‘skinny jabs' and helps you lose weight even faster, study suggests
The new weight loss pill has seen promising results and offers hope to millions WEIGH TO GO New 'Ozempic pill' is better than 'skinny jabs' and helps you lose weight even faster, study suggests Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A NEW 'Ozempic pill' leads to faster weight loss than the popular 'skinny jabs', studies have suggested. The new weight loss medication, which can also be offered by injection, can help patients lose a significant amount of weight. Sign up for Scottish Sun newsletter Sign up 1 The new weight loss pill has seen promising results in early trials Credit: Getty An early study found that patients who received amycretin as a weekly jab lost 24% of their body weight after 36 weeks of treatment. But initial trials assessing a tablet form of the jab saw promising results with patients losing an average 13% of bodyweight in just three months. This suggests the drug leads to greater weight loss than Wegovy, the 'sister jab' of Ozempic. Such treatments have been called transformative by NHS leaders. It's estimated that around 1.5 million Brits currently receive weight loss jabs through specialist weight loss services or private prescriptions. But weight pills offer a new hope to millions looking to lose weight as the injections put additional pressure on an overstretched NHS. However, further clinical trials are needed before the treatment can be made available in the UK. This could take several years and there's no guarantee that regulators will approve the use of the drug. Amycretin, made by Novo Nordisk, contains semaglutide, the same active ingredient as Ozempic and Wegovy and helps control blood sugar and appetite. It targets specific receptors in the body - the GLP-1 and amylin receptors - helping you feel full and stops overeating. An early trial published in The Lancet found that 125 adults taking weekly injections containing higher doses of the drug lost nearly a quarter of their body weight after 36 weeks. It also showed signs of improving blood sugar levels. However, there were some mild to moderate side effects including nausea and vomiting but these were resolved by the end of the treatment. Experts said that the medicine appeared "safe and tolerable" but further studies were needed to fully assess the drug. But a second trial, also published in The Lancet, assessed the drug in tablet form in 144 people. Those taking the highest dose of 100mg lost 13% of their body weight over four months. Weight Loss Jabs - Pros vs Cons The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people who were overweight or obese. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." As with the first trial, there were also some mild to moderate side effects including loss of appetite and similar gastrointestinal issues. It comes as a separate study examined the effects of the weight-loss jab, Wegovy, at higher doses. The researchers found that giving patients 7.2mg of Wegovy once a week led to an average weight loss of 21%, with a third of participants losing 25% of their body weight over 72 weeks. The studies were also presented to the American Diabetes Association's Scientific Sessions in Chicago.
